` TAL (Taro Pharmaceutical Industries Ltd) vs DAX Index Comparison - Alpha Spread

TAL
vs
D
DAX Index

Over the past 12 months, TAL has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +13% growth.

Stocks Performance
TAL vs DAX Index

Loading
TAL
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TAL vs DAX Index

Loading
TAL
DAX Index
Difference
www.alphaspread.com

Performance By Year
TAL vs DAX Index

Loading
TAL
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Taro Pharmaceutical Industries Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Taro Pharmaceutical Industries Ltd
Glance View

Market Cap
1.5B EUR
Industry
Pharmaceuticals

In the often-underappreciated realm of generic pharmaceuticals, Taro Pharmaceutical Industries Ltd. has carved out a notable niche for itself. Founded in 1950 in Haifa, Israel, Taro's journey began with a focus on dermatological products, a specialism that continues to be at the heart of its operations. As generic drug prices have become increasingly competitive, Taro has distinguished itself through a robust portfolio that not only includes dermatology but also topical and oral medications across various therapeutic areas. The company's commitment to quality and cost-effective drug solutions stems from its strategic use of rigorous R&D efforts, channeling years of scientific expertise to bring affordable healthcare solutions to markets worldwide. In essence, Taro crafts a business model that balances operational efficiency with the nuanced complexities of pharmaceutical manufacturing and compliance. Underpinning Taro's business strategy is its prowess in generic drug manufacture, where it maximizes its revenue by capitalizing on patent expirations from mainstream pharmaceutical enterprises. With its deep understanding of regulatory frameworks and market dynamics, Taro adeptly navigates the intricate landscapes of the U.S. and international markets, leveraging its wide distribution network. The United States, being a major revenue driver, reflects Taro's prowess and its ability to quickly adapt to drug lifecycle shifts. Yet, Taro's success isn't solely attributed to scale but also to its meticulous cost management and operational synergies across its global facilities. This orchestration allows it to maintain competitive pricing while ensuring high-quality standards - a testament to its deep-rooted industry experience and strategic foresight.

TAL Intrinsic Value
Not Available
Back to Top